TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23798058

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with bowel resection
Number of subjects: 203

Group type: COMPARATOR
Intervention: Laparoscopic surgery without bowel resection
Number of subjects: 203
Study: 21232078

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 61
Study: 18999322

Group type: EXPERIMENTAL
Intervention: Welfare programs that increased maternal employment and family income
Number of subjects: 0
Study: 17051119

Group type: EXPERIMENTAL
Intervention: Platelet plasma growth factors
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control areas (no treatment)
Number of subjects: 20
Study: 12494247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trial duration
Number of subjects: 35
Study: 11078252

Group type: EXPERIMENTAL
Intervention: Intravenous ethanol administration (60 ml of 100 proof ethanol)
Number of subjects: 18
Study: 8985569

Group type: EXPERIMENTAL
Intervention: Adhesive pre-coated brackets
Number of subjects: 38

Group type: COMPARATOR
Intervention: No-mix adhesive (Control)
Number of subjects: 38
Study: 1526058

Group type: EXPERIMENTAL
Intervention: Aerosol spray (Otomize)
Number of subjects: 0
Study: 6545095

Group type: EXPERIMENTAL
Intervention: Pre-operative explanation of the study
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Participation in the study
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Breathing tests
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Willingness to volunteer for future studies
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Influence of age and surgery on attitudes
Number of subjects: 32
Study: 29984804

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor‐2 treatment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Observational group
Number of subjects: 134
Study: 27709280

Group type: EXPERIMENTAL
Intervention: Total-body computed tomography (TBCT)
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Standard work-up (STWU)
Number of subjects: 1083
Study: 25663125

Group type: COMPARATOR
Intervention: CF-HAIC (Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ACF-HAIC (Adriamycin 50 mg/m2 on day 1, Cisplatin 60 mg/m2 on day 2, 5-FU 500 mg/m2 on days 1-3)
Number of subjects: 56
Study: 23282217

Group type: EXPERIMENTAL
Intervention: 1-hour online self-regulation intervention
Number of subjects: 791

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 791
Study: 22027669

Group type: EXPERIMENTAL
Intervention: Topamax (topiramate) as mono-therapy (8 children) and combined therapy (22 children) with a mean treatment dose of 5.9 mg/kg per day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topamax (topiramate)
Number of subjects: 30
Study: 18638266

Group type: EXPERIMENTAL
Intervention: Topical Negative Pressure (TNP) therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional gauze therapy
Number of subjects: 33
Study: 16619056

Group type: EXPERIMENTAL
Intervention: Oxyntomodulin administration
Number of subjects: 15
Study: 14508884

Group type: EXPERIMENTAL
Intervention: MBI-226 gel formulation
Number of subjects: 0
Study: 11045863

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 9187996

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (4 x 10(‐12) to 1 x 10(‐4) mol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (10(‐9) to 10(‐8) mol/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 1568371

Group type: EXPERIMENTAL
Intervention: Single i.v. administration of 2 g ceftazidime concurrent with anesthesia induction (group 1)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Short-term prophylaxis with 1 g ceftazidime administered preanesthesia, 30 min before surgery and 6 and 12 hrs after the first dose (group 2)
Number of subjects: 392
Study: 2859775

Group type: EXPERIMENTAL
Intervention: Acebutolol 100 mg three times a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg three times a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol 600 mg three times a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propranolol 30 mg three times a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propranolol 60 mg three times a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propranolol 180 mg three times a day
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acebutolol 1 mg/kg infused over 15 minutes
Number of subjects: 21
Study: 31763746

Group type: EXPERIMENTAL
Intervention: ACTIVATE intervention (wearable-based intervention to increase physical activity and reduce sedentary behavior)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: ACTIVATE intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83
Study: 29996854

Group type: EXPERIMENTAL
Intervention: ARMADILLO intervention providing SRH information via text message
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm 3 with varying interactions by site (Kenya and Peru)
Number of subjects: 0
Study: 27097970

Group type: EXPERIMENTAL
Intervention: DCs/CIKs combined with thoracic radiotherapy (TRT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: TRT alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DCs/CIKs combined with TRT
Number of subjects: 82
Study: 24045444

Group type: EXPERIMENTAL
Intervention: Retaining outer gloves for 1 hour into the case
Number of subjects: 353

Group type: COMPARATOR
Intervention: Exchanging outer gloves for 1 hour into the case
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cloth gowns
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Paper gowns
Number of subjects: 353

Group type: COMPARATOR
Intervention: Cloth gowns in strike-through study
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Paper gowns in strike-through study
Number of subjects: 353
Study: 22498020

Group type: EXPERIMENTAL
Intervention: Educational intervention program (adaptation of the asthma, sport and health program)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Educational intervention program (after 3 months)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 138
Study: 20980998

Group type: COMPARATOR
Intervention: Twice-weekly kisspeptin-54 (KP-54) injections for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily kisspeptin-54 (KP-54) injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 0
Study: 18591698

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) 1 mg.kg(‐1) iv, 30 min before and six hours after skin incision
Number of subjects: 40
Study: 17380846

Group type: EXPERIMENTAL
Intervention: Dihydropyridines (DHP) treatment
Number of subjects: 54
Study: 15038587

Group type: EXPERIMENTAL
Intervention: R-ORS
Number of subjects: 113
Study: 10809917

Group type: EXPERIMENTAL
Intervention: CD4+ IFNgamma mRNA expressing lymphocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8+ IFNgamma mRNA expressing lymphocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4+ and CD8+ IFNgamma mRNA expressing cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 8646827

Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion in small dorsal hand veins at skin temperatures < 29.0 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalaprilat infusion in small dorsal hand veins at skin temperatures > 31 degrees C with norepinephrine preconstriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin-mediated vasodilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin-mediated vasodilation
Number of subjects: 0
Study: 1633323

Group type: EXPERIMENTAL
Intervention: ASA 300 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ASA 500 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 12
Study: 6500225

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg four times a day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg four times a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31704789

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Thoracic paravertebral block (TPVB) with continuous infusion of 0.2% levobupivacaine (8 mL/hour) after a 20 mL bolus.
Number of subjects: 88
Study: 29190357

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT), 12 sessions of 50 minutes each over 6 months
Number of subjects: 273
Study: 27631268

Group type: EXPERIMENTAL
Intervention: Piezosurgery device
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-speed drill
Number of subjects: 42
Study: 25104527

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13642

Group type: EXPERIMENTAL
Intervention: Edoxaban high dose
Number of subjects: 13642

Group type: EXPERIMENTAL
Intervention: Edoxaban low dose
Number of subjects: 13642

Group type: EXPERIMENTAL
Intervention: Open-label VKA
Number of subjects: 13642

Group type: EXPERIMENTAL
Intervention: Open-label NOAC
Number of subjects: 13642
Study: 22142173

Group type: EXPERIMENTAL
Intervention: 4-lesson vegetable-focused intervention
Number of subjects: 1937

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1937
Study: 20598836

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18056740

Group type: EXPERIMENTAL
Intervention: Bipolar cemented hemiarthroplasty
Number of subjects: 222

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 222
Study: 15891131

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus artesunate (SP-AS)
Number of subjects: 197
Study: 11788219

Group type: EXPERIMENTAL
Intervention: Gamma irradiation (iridium-192)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 10090162

Group type: EXPERIMENTAL
Intervention: CyA microemulsion (Neoral)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional CyA (Sandimmun)
Number of subjects: 51
Study: 7751734

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (LFLX) 100 mg or 300 mg, administered as a single dose.
Number of subjects: 101
Study: 2303583

Group type: EXPERIMENTAL
Intervention: Ibuprofen/codeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin/codeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All active treatment groups (including ibuprofen/codeine and aspirin/codeine)
Number of subjects: 0
Study: 7026247

Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 63732

Group type: COMPARATOR
Intervention: Control group (factories not receiving intervention)
Number of subjects: 63732

Group type: EXPERIMENTAL
Intervention: Belgium (intervention group)
Number of subjects: 63732

Group type: EXPERIMENTAL
Intervention: Poland (intervention group)
Number of subjects: 63732
Study: 30553570

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A(H5N1) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unadjuvanted A(H5N1) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A(H5N1) vaccine antigen
Number of subjects: 0
Study: 28386782

Group type: EXPERIMENTAL
Intervention: 2.0 mm × 9.0 mm screws for intermaxillary fixation (IMF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: 2.0 mm noncompression miniplates
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study: 25133644

Group type: EXPERIMENTAL
Intervention: 36 hours after hCG injection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 42 hours after hCG injection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 48 hours after hCG injection
Number of subjects: 92
Study: 23675676

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity
Number of subjects: 11140

Group type: COMPARATOR
Intervention: No or mild physical activity
Number of subjects: 11140
Study: 21546726

Group type: EXPERIMENTAL
Intervention: Primary closure with omental patch
Number of subjects: 176

Group type: COMPARATOR
Intervention: Only primary closure
Number of subjects: 176
Study: 19366848

Group type: EXPERIMENTAL
Intervention: Nestorone (NES) gel 2 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Nestorone (NES) gel 4 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Testosterone (T) gel 10 g
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 2 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 4 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 6 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: T gel 10 g plus NES gel 8 mg
Number of subjects: 140
Study: 18190254

Group type: EXPERIMENTAL
Intervention: Recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3‐O‐desacyl‐4'‐monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 15077888

Group type: EXPERIMENTAL
Intervention: Snoring prevalence
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Snoring prevalence among males
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Snoring prevalence among females
Number of subjects: 1252

Group type: EXPERIMENTAL
Intervention: Age-related snoring prevalence
Number of subjects: 1252
Study: 11480325

Group type: EXPERIMENTAL
Intervention: Low-sodium hypotonic oral rehydration solution (LSORS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard WHO oral rehydration solution (STORS)
Number of subjects: 117
Study: 9497194

Group type: EXPERIMENTAL
Intervention: gluten-free diet for 1 year
Number of subjects: 40

Group type: COMPARATOR
Intervention: total villous atrophy
Number of subjects: 40
Study: 7974683

Group type: EXPERIMENTAL
Intervention: Albendazole with surgery (ABZ surgery group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Surgery alone (non-ABZ surgery group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Albendazole treatment alone (ABZ CE group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Albendazole with surgical intervention (ABZ AE group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Albendazole alone (ABZ AE group)
Number of subjects: 34
Study: 2786292

Group type: EXPERIMENTAL
Intervention: Leucovorin calcium 25 mg (formulation 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leucovorin calcium 25 mg (formulation 2)
Number of subjects: 36
Study: 5795804

Group type: EXPERIMENTAL
Intervention: Pentazocine (10 mg, 20 mg, 40 mg)
Number of subjects: 1074

Group type: COMPARATOR
Intervention: Morphine (5 mg, 10 mg)
Number of subjects: 1074
Study: 31272682

Group type: EXPERIMENTAL
Intervention: Aggressive respiratory rehabilitation (inspiratory training with an incentive spirometer, Coach 2®PORTEX) starting from day five postoperatively, performed four times a day and continued at home after discharge.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no respiratory rehabilitation).
Number of subjects: 34
Study: 30903221

Group type: EXPERIMENTAL
Intervention: Mid-flexion (30°)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extension (0°)
Number of subjects: 40
Study: 27080998

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) of auricular acupressure, performed twice a week for 4 weeks at each acupoint for 30 seconds.
Number of subjects: 100

Group type: COMPARATOR
Intervention: No electrical stimulation (no-ES) under auricular acupressure (control group).
Number of subjects: 100
Study: 26002840

Group type: EXPERIMENTAL
Intervention: stavudine (d4T) switching to zidovudine (ZDV) at 24 weeks
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: zidovudine (ZDV)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: tenofovir (TDF)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All ART regimens combined with nevirapine
Number of subjects: 150
Study: 23344779

Group type: EXPERIMENTAL
Intervention: FeNO measurement in children with AR
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: FeNO measurement in children with combined AR and asthma
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of FeNO and HDM-specific IgE
Number of subjects: 251
Study: 21729167

Group type: EXPERIMENTAL
Intervention: Self‐estimated UV sensitivity according to Fitzpatrick's classification
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Actual UV sensitivity measured by phototest
Number of subjects: 166
Study: 19372329

Group type: EXPERIMENTAL
Intervention: Remifentanil at 4 ng/mL (Group R4)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil at 2 ng/mL (Group R2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil at 3 ng/mL (Group R3)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil at 1 ng/mL (Group R1)
Number of subjects: 100
Study: 16415283

Group type: EXPERIMENTAL
Intervention: Monochloroacetic acid and 10% formaldehyde
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10% formaldehyde alone
Number of subjects: 57
Study: 15499823

Group type: EXPERIMENTAL
Intervention: Children who were questioned about truth and lies and promised to tell the truth before the second interview.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Children who were questioned without prior discussion about truth and lies or a promise to tell the truth.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Children in Experiment 1 when the likelihood of being blamed for the transgression was reduced.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Children's moral understanding of truth- and lie-telling assessed by a second interviewer.
Number of subjects: 201
Study: 11672921

Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine (conjugate-conjugate)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 7-valent conjugate vaccine followed by 23-valent polysaccharide vaccine (conjugate-polysaccharide)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (placebo-polysaccharide)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (placebo-placebo)
Number of subjects: 67
Study: 9039508

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (4 mg/kg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 16
Study: 8086602

Group type: EXPERIMENTAL
Intervention: Models for three-dimensional contingency tables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum likelihood methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional goodness-of-fit test statistics
Number of subjects: 0
Study: 3111615

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (1 g twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31734702

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 381

Group type: COMPARATOR
Intervention: Face-to-Face training
Number of subjects: 381
Study: 29391310

Group type: EXPERIMENTAL
Intervention: PEG-3350+SD+B
Number of subjects: 150

Group type: COMPARATOR
Intervention: PEG-AA
Number of subjects: 150
Study: 27212005

Group type: COMPARATOR
Intervention: Axillary ultrasound (AUS) - no further axillary staging (arm 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) - axillary staging (arm 2)
Number of subjects: 68
Study: 23782595

Group type: EXPERIMENTAL
Intervention: Low fluidic settings
Number of subjects: 57

Group type: COMPARATOR
Intervention: High fluidic settings
Number of subjects: 57
Study: 22302136

Group type: EXPERIMENTAL
Intervention: Once-weekly etanercept (OW) 25 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Twice-weekly etanercept (TW) 25 mg
Number of subjects: 63
Study: 20201949

Group type: EXPERIMENTAL
Intervention: 3 cycles of CHOP followed by BEAM autograft
Number of subjects: 457

Group type: COMPARATOR
Intervention: Continuing CHOP
Number of subjects: 457
Study: 17577653

Group type: EXPERIMENTAL
Intervention: 1-month recall period
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 1-month rating task
Number of subjects: 156
Study: 15881624

Group type: EXPERIMENTAL
Intervention: Quetiapine treatment (up to 600 mg/day)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Quetiapine treatment
Number of subjects: 38
Study: 12021647

Group type: EXPERIMENTAL
Intervention: Orbital CT scans showing optic nerve crowding
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Orbital CT scans showing intracranial fat prolapse
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Muscle index greater than 50%
Number of subjects: 27

Group type: COMPARATOR
Intervention: Superior ophthalmic vein dilation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Proptosis
Number of subjects: 27
Study: 10705056

Group type: EXPERIMENTAL
Intervention: Fusidic acid 500 mg q8h orally for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: No anti-staphylococcal treatment (Control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fusidic acid treatment
Number of subjects: 16
Study: 9376241

Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia (PCA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional intravenous analgesia
Number of subjects: 30
Study: 8443851

Group type: EXPERIMENTAL
Intervention: Rocuronium 120, 160, 200, or 240 micrograms.kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rocuronium cumulative dose-response
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rocuronium administration
Number of subjects: 100
Study: 3021638

Group type: EXPERIMENTAL
Intervention: Stress inoculation training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo/information training
Number of subjects: 54
Study: 30321440

Group type: EXPERIMENTAL
Intervention: Psychosensory therapy (Havening)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no psychosensory therapy)
Number of subjects: 41